Stock Price & Recent Performance Equifax’s stock has been range-bound in recent weeks, hovering in the low-$230s per share. It closed at $231.12 on Oct. 20investing.com, and despite a solid year-to-date performance in 2025, shares remain about 15% lower than a year agoinvesting.com. Elevated interest rates and recession worries weighed on credit industry stocks earlier this year. However, sentiment has improved recently as the Federal Reserve’s policy outlook turned more dovish this fall and tech-focused stocks rebounded. Equifax stock is up roughly 2% for 2025 so far, outperforming some peers, and has climbed about 50% over the past five years

Earnings Beat Drives Stock Higher Elevance Health posted strong third-quarter 2025 results, significantly outperforming market expectations on both profit and revenue. Adjusted earnings came in at $6.03 per share, well above the ~$4.95 analysts predictedinvesting.com. Likewise, revenue for the quarter reached $50.1 billion, surpassing the $49.3 billion consensus and growing 12% year-over-yearinvesting.com. This robust growth was fueled by higher premium yields and an expanding customer base – particularly gains in Medicare Advantage enrollments – along with contributions from recent acquisitions in Elevance’s Carelon health services unittradingview.com. These factors combined to help Elevance smash its Q3 forecasts, showcasing strong demand and pricing power

Danaher Stock Price and Recent Performance Danaher’s shares have been on a steady climb in recent weeks, hovering around the $208 mark as of October 21, 2025. This puts the stock roughly back to early-year levels and marks a solid rebound from its summer lows. In fact, DHR has gained about 8% over the past month and 10% over the past quarter, outpacing many peers in the life sciences sectorts2.tech. This rally suggests renewed investor interest in Danaher and its industry, possibly driven by anticipation of the Q3 earnings and optimism around new product developments. Despite the recent uptick, it’s